

## STEP 1 Content Outline

### 1. General Principles

#### 1.1 Biochemistry and molecular biology

- 1.1.1 gene expression: DNA structure, replication, and exchange
  - 1.1.1.1 DNA structure: single- and double-stranded DNA, stabilizing forces, supercoiling
  - 1.1.1.2 analysis of DNA: sequencing, restriction analysis, PCR amplification, hybridization
  - 1.1.1.3 DNA replication, mutation, repair, degradation, and inactivation
  - 1.1.1.4 gene structure and organization; chromosomes; centromere, telomere
  - 1.1.1.5 recombination, insertion sequences, transposons
  - 1.1.1.6 mechanisms of genetic exchange, including transformation, transduction, conjugation, crossover, recombination, linkage
  - 1.1.1.7 plasmids and bacteriophages
- 1.1.2 gene expression: transcription, including defects
  - 1.1.2.1 transcription of DNA into RNA, enzymatic reactions, RNA, RNA degradation
  - 1.1.2.2 regulation: cis-regulatory elements, transcription factors, enhancers, promoters, silencers, repressants, splicing
- 1.1.3 gene expression: translation, including defects
  - 1.1.3.1 the genetic code
  - 1.1.3.2 structure and function of tRNA
  - 1.1.3.3 structure and function of ribosomes
  - 1.1.3.4 protein synthesis
  - 1.1.3.5 regulation of translation
  - 1.1.3.6 post-translational modifications, including phosphorylation, addition of CHO units
  - 1.1.3.7 protein degradation
- 1.1.4 structure and function of proteins
  - 1.1.4.1 principles of protein structure and folding
  - 1.1.4.2 enzymes: kinetics, reaction mechanisms
  - 1.1.4.3 structural and regulatory proteins: ligand binding, self-assembly
  - 1.1.4.4 regulatory properties
- 1.1.5 energy metabolism, including metabolic sequences and regulation
  - 1.1.5.1 generation of energy from carbohydrates, fatty acids, and essential amino acids; glycolysis, pentose phosphate pathway, tricarboxylic acid cycle, ketogenesis, electron transport and oxidative phosphorylation, glycogenolysis
  - 1.1.5.2 storage of energy: gluconeogenesis, glycogenesis, fatty acid and triglyceride synthesis
  - 1.1.5.3 thermodynamics: free energy, chemical equilibria and group transfer potential, energetics of ATP and other high-energy compounds
- 1.1.6 metabolic pathways of small molecules and associated diseases
  - 1.1.6.1 biosynthesis and degradation of amino acids (eg, homocystinuria; maple syrup urine disease)
  - 1.1.6.2 biosynthesis and degradation of purine and pyrimidine nucleotides

- 1.1.6.3 biosynthesis and degradation of lipids (eg, dyslipidemias, carnitine deficiency)
- 1.1.6.4 biosynthesis and degradation of porphyrins
- 1.1.6.5 galactosemia and other small sugar disorders
- 1.1.6.6 biosynthesis and degradation of alcohols and other small molecules
- 1.1.7 biosynthesis and degradation of other macromolecules and associated abnormalities, complex carbohydrates (eg, lysosomal storage disease), glycoproteins, and proteoglycans (eg, type II glycogen storage disease)

## **1.2 Biology of cells**

- 1.2.1 structure and function of cell components
  - 1.2.1.1 endoplasmic reticulum
  - 1.2.1.2 Golgi complex
  - 1.2.1.3 mitochondria
  - 1.2.1.4 lysosome, peroxisome, endosome
  - 1.2.1.5 centriole, microtubule
  - 1.2.1.6 ribosome, polysome
  - 1.2.1.7 plasma membrane (eg, glycolipids, glycoproteins, glycosaminoglycans, membrane fluidity)
  - 1.2.1.8 cytosol
  - 1.2.1.9 cilia
  - 1.2.1.10 nucleus, including chromatin, nucleolus, the nuclear envelope, and nuclear matrix
  - 1.2.1.11 cytoskeleton (eg, actin filaments, intermediate filaments, microtubules)
- 1.2.2 signal transduction
  - 1.2.2.1 basic principles: autocrine, paracrine, endocrine
  - 1.2.2.2 receptors and channels
    - 1.2.2.2.1 protein kinase receptors
    - 1.2.2.2.2 non-protein kinase receptors
    - 1.2.2.2.3 nuclear receptors
    - 1.2.2.2.4 G protein-linked receptors
    - 1.2.2.2.5 voltage-gated channels
    - 1.2.2.2.6 ligand-gated channels
  - 1.2.2.3 second messengers (eg, IP<sub>3</sub>, DAG, PKA, PKC)
  - 1.2.2.4 signal transduction pathways (eg, MAPK, JNK, TGF-β)
- 1.2.3 cell-cell and cell-matrix adhesion
- 1.2.4 cell motility
- 1.2.5 intracellular sorting (eg, trafficking, endocytosis)
- 1.2.6 cellular homeostasis (eg, turnover, pH maintenance, proteasome, ions, soluble proteins)
- 1.2.7 cell cycle
  - 1.2.7.1 mitosis
  - 1.2.7.2 meiosis
  - 1.2.7.3 structure of spindle apparatus
  - 1.2.7.4 cell cycle regulation (eg, cyclins, cdks, cdk inhibitors)
- 1.2.8 structure and function of basic tissue components
  - 1.2.8.1 epithelial cells
  - 1.2.8.2 connective tissue cells (eg, fibroblasts)
  - 1.2.8.3 muscle cells
  - 1.2.8.4 nerve cells

- 1.2.8.5 extracellular matrix (eg, basement membranes)
- 1.2.9 adaptive cell response to injury
- 1.2.10 intracellular accumulations (eg, pigments, fats, proteins, carbohydrates, minerals, inclusions, vacuoles)
- 1.2.11 mechanisms of injury and necrosis
- 1.2.12 apoptosis

### **1.3 Human development and genetics**

- 1.3.1 embryogenesis: programmed gene expression, tissue differentiation and morphogenesis, homeotic genes; developmental regulation of gene expression
- 1.3.2 congenital abnormalities: principles, patterns of anomalies, dysmorphogenesis
- 1.3.3 principles of pedigree analysis
  - 1.3.3.1 inheritance patterns
  - 1.3.3.2 occurrence and recurrence risk determination
- 1.3.4 population genetics: Hardy-Weinberg law, founder effects, mutation-selection equilibrium
- 1.3.5 genetic mechanisms
  - 1.3.5.1 chromosomal abnormalities: translocations; deletions; duplications, including nucleotide repeats and inversions, mosaicism
  - 1.3.5.2 mendelian inheritance
    - 1.3.5.2.1 homozygosity, heterozygosity
    - 1.3.5.2.2 phenotypic variation: pleiotropy, variable expression, delayed onset
    - 1.3.5.2.3 imprinting
    - 1.3.5.2.4 polymorphisms
  - 1.3.5.3 multifactorial diseases
- 1.3.6 clinical genetics
  - 1.3.6.1 genetic testing
  - 1.3.6.2 prenatal diagnosis
  - 1.3.6.3 newborn screening
  - 1.3.6.4 genetic counseling: ethics
  - 1.3.6.5 gene therapy

### **1.4 Biology of tissue response to disease**

- 1.4.1 inflammation, including cells and mediators
  - 1.4.1.1 acute inflammation and mediator systems
  - 1.4.1.2 vascular response to injury, including mediators
  - 1.4.1.3 inflammatory cell recruitment, including adherence and cell migration, and phagocytosis
  - 1.4.1.4 bactericidal mechanisms and tissue injury
  - 1.4.1.5 clinical manifestations (eg, pain, fever, leukocytosis, leukemoid reaction, chills)
  - 1.4.1.6 chronic inflammation
- 1.4.2 reparative processes
  - 1.4.2.1 wound healing, hemostasis, and repair: thrombosis, granulation tissue, angiogenesis, fibrosis, scar/keloid formation
  - 1.4.2.2 regenerative processes
- 1.4.3 neoplasia
  - 1.4.3.1 classification of neoplasms; histologic diagnosis of malignancy
  - 1.4.3.2 grading and staging of neoplasms

- 1.4.3.3 cell biology, biochemistry, and molecular biology of neoplastic cells: transformation, oncogenes, altered cell differentiation and proliferation
- 1.4.3.4 hereditary neoplastic disorders
- 1.4.3.5 invasion and metastasis
- 1.4.3.6 tumor immunology
- 1.4.3.7 paraneoplastic manifestations of cancer
- 1.4.3.8 cancer epidemiology and prevention

## **1.5 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 1.5.1 progression through the life cycle, including birth through senescence
  - 1.5.1.1 cognitive, language, motor skills, and social and interpersonal development
  - 1.5.1.2 sexual development (eg, puberty, menopause)
  - 1.5.1.3 influence of developmental stage on physician-patient interview
- 1.5.2 psychologic and social factors influencing patient behavior
  - 1.5.2.1 personality traits or coping style, including coping mechanisms
  - 1.5.2.2 psychodynamic and behavioral factors, related past experience
  - 1.5.2.3 family and cultural factors, including socioeconomic status, ethnicity, and gender
  - 1.5.2.4 adaptive behavioral responses to stress and illness
  - 1.5.2.5 maladaptive behavioral responses to stress and illness (eg, drug-seeking behavior, sleep deprivation)
  - 1.5.2.6 interactions between the patient and the physician or the health care system (eg, transference)
  - 1.5.2.7 patient adherence
    - 1.5.2.7.1 general
    - 1.5.2.7.2 adolescent
- 1.5.3 patient interviewing, consultation, and interactions with the family
  - 1.5.3.1 establishing and maintaining rapport
  - 1.5.3.2 data gathering
  - 1.5.3.3 approaches to patient education
  - 1.5.3.4 enticing patients to make lifestyle changes
  - 1.5.3.5 communicating bad news
  - 1.5.3.6 “difficult” interviews (eg, anxious or angry patients)
  - 1.5.3.7 multicultural ethnic characteristics
- 1.5.4 medical ethics, jurisprudence, and professional behavior
  - 1.5.4.1 consent and informed consent to treatment
  - 1.5.4.2 physician-patient relationships (eg, ethical conduct, confidentiality)
  - 1.5.4.3 death and dying
  - 1.5.4.4 birth-related issues
  - 1.5.4.5 issues related to patient participation in research
  - 1.5.4.6 interactions with other health professionals (eg, referral)
  - 1.5.4.7 sexuality and the profession; other “boundary” issues
  - 1.5.4.8 ethics of managed care
  - 1.5.4.9 organization and cost of health care delivery

## **1.6 Multisystem processes**

- 1.6.1 nutrition

- 1.6.1.1 generation, expenditure, and storage of energy at the whole-body level
- 1.6.1.2 assessment of nutritional status across the life span, including calories, protein, essential nutrients, hypoalimentation
- 1.6.1.3 functions of nutrients, including essential, trans-fatty acids, cholesterol
- 1.6.1.4 protein-calorie malnutrition
- 1.6.1.5 vitamin deficiencies and/or toxicities
  - 1.6.1.5.1 vitamin A
  - 1.6.1.5.2 vitamin B complex
  - 1.6.1.5.3 vitamin C
  - 1.6.1.5.4 vitamin D
  - 1.6.1.5.5 vitamin E
  - 1.6.1.5.6 vitamin K
- 1.6.1.6 mineral deficiencies and toxicities
- 1.6.1.7 eating disorders
  - 1.6.1.7.1 obesity
  - 1.6.1.7.2 anorexia and bulimia
  - 1.6.1.7.3 alternative diets, nutritional supplements, and food fads
  - 1.6.1.7.4 treatment of eating disorders
- 1.6.2 temperature regulation
- 1.6.3 adaptation to environmental extremes, including occupational exposures
  - 1.6.3.1 physical and associated disorders
    - 1.6.3.1.1 temperature
    - 1.6.3.1.2 radiation
    - 1.6.3.1.3 burns, including electrocution, lightning
    - 1.6.3.1.4 decreased atmospheric pressure, high-altitude sickness
    - 1.6.3.1.5 increased water pressure (eg, “bends”)
  - 1.6.3.2 chemical
    - 1.6.3.2.1 gases, vapors, smoke inhalation (eg, poison gases)
    - 1.6.3.2.2 agricultural hazards (eg, insecticides)
    - 1.6.3.2.3 volatile organic solvents (eg, chloroform)
    - 1.6.3.2.4 heavy metals (eg, lead)
    - 1.6.3.2.5 principles of poisoning and therapy
- 1.6.4 fluid, electrolyte, and acid-base balance and disorders (eg, dehydration, acidosis, alkalosis)

## **1.7 Pharmacodynamic and pharmacokinetic processes**

- 1.7.1 general principles
  - 1.7.1.1 pharmacokinetics: absorption, distribution, metabolism, excretion, dosage intervals
  - 1.7.1.2 mechanisms of drug action, structure-activity relationships
  - 1.7.1.3 concentration- and dose-effect relationships (eg, efficacy, potency), types of agonists (eg, full, partial, inverse) and antagonists and their actions
  - 1.7.1.4 individual factors altering pharmacokinetics and pharmacodynamics (eg, age, gender, disease, tolerance, compliance, body weight, metabolic proficiency, pharmacogenetics)
  - 1.7.1.5 drug side effects, overdosage, toxicology
  - 1.7.1.6 drug interactions

- 1.7.1.7 regulatory issues (eg, drug development, approval, scheduling)
- 1.7.2 general properties of autacoids
  - 1.7.2.1 peptides and analogs
  - 1.7.2.2 biogenic amines
  - 1.7.2.3 prostanoids and their inhibitors
  - 1.7.2.4 smooth muscle/endothelial autacoids (eg, nitric oxide)
- 1.7.3 general principles of autonomic pharmacology
- 1.7.4 general properties of antimicrobials, including mechanisms of action and resistance
  - 1.7.4.1 antibacterials
    - 1.7.4A aminoglycosides
    - 1.7.4B cephalosporins and penicillins
    - 1.7.4C quinolones and tetracyclines
    - 1.7.4D antituberculous
    - 1.7.4E other antibacterials
  - 1.7.4.2 antivirals
    - 1.7.4F antiretrovirals
    - 1.7.4G other antivirals
  - 1.7.4.3 antifungals
    - 1.7.4H antifungals
  - 1.7.4.4 antiparasitics
    - 1.7.4E antiparasitics
- 1.7.5 general properties of antineoplastic agents and immunosuppressants, including drug effects on rapidly dividing mammalian cells

## **1.8 Microbial biology and infection**

- 1.8.1 microbial classification and its basis
- 1.8.2 bacteria and bacterial diseases
  - 1.8.2.1 structure and composition
  - 1.8.2.2 metabolism, physiology, and regulation
  - 1.8.2.3 genetics
  - 1.8.2.4 nature and mechanisms of action of virulence factors
  - 1.8.2.5 pathophysiology of infection
  - 1.8.2.6 epidemiology and ecology
  - 1.8.2.7 principles of cultivation, assay, and laboratory diagnosis
- 1.8.3 viruses and viral diseases
  - 1.8.3.1 physical and chemical properties
  - 1.8.3.2 replication
  - 1.8.3.3 genetics
  - 1.8.3.4 principles of cultivation, assay, and laboratory diagnosis
  - 1.8.3.5 molecular basis of pathogenesis
  - 1.8.3.6 pathophysiology of infection
  - 1.8.3.7 latent and persistent infections
  - 1.8.3.8 epidemiology
  - 1.8.3.9 oncogenic viruses
- 1.8.4 fungi and fungal infections
  - 1.8.4.1 structure, physiology, cultivation, and laboratory diagnosis
  - 1.8.4.2 pathogenesis and epidemiology
- 1.8.5 parasites and parasitic diseases

- 1.8.5.1 structure, physiology, and laboratory diagnosis
- 1.8.5.2 pathogenesis and epidemiology
- 1.8.6 principles of sterilization and pure culture technique

## **1.9 Immune responses**

- 1.9.1 production and function of granulocytes, natural killer cells, and macrophages
- 1.9.2 production and function of T lymphocytes, T-lymphocyte receptors
- 1.9.3 production and function of B lymphocytes and plasma cells; immunoglobulin and antibodies: structure and biologic properties
- 1.9.4 antigenicity and immunogenicity; antigen presentation; cell activation and regulation; tolerance and clonal deletion
- 1.9.5 immunologic mediators: chemistry, function, molecular biology, classic and alternative complement pathways, cytokines, chemokines
- 1.9.6 immunogenetics; MHC structure and function, class I, II molecules; erythrocyte antigens
- 1.9.7 immunizations: vaccines, protective immunity
- 1.9.8 alterations in immunologic function
  - 1.9.8.1 T- or B-lymphocyte deficiencies (DiGeorge syndrome)
  - 1.9.8.2 deficiencies of phagocytic cells
  - 1.9.8.3 combined immunodeficiency disease
  - 1.9.8.4 HIV infection/AIDS and other acquired disorders of immune responsiveness
  - 1.9.8.5 drug-induced alterations in immune responses, immunopharmacology
- 1.9.9 immunologically mediated disorders
  - 1.9.9.1 type I, type II, type III hypersensitivity
  - 1.9.9.2 type IV hypersensitivity
  - 1.9.9.3 transplant and transplant rejection
  - 1.9.9.4 autoimmune disorders
  - 1.9.9.5 risks of transplantation, transfusion (eg, graft-versus-host disease)
  - 1.9.9.6 isoimmunization, hemolytic disease of the newborn
  - 1.9.9.7 immunopathogenesis
- 1.9.10 immunologic principles underlying diagnostic laboratory tests (eg, ELISA, complement fixation, RIA, agglutination)
- 1.9.11 innate immunity

## **1.10 Quantitative methods**

- 1.10.1 fundamental concepts of measurement
  - 1.10.1.1 scales of measurement
  - 1.10.1.2 distribution, central tendency, variability, probability
  - 1.10.1.3 disease prevalence and incidence
  - 1.10.1.4 disease outcomes (eg, fatality rates)
  - 1.10.1.5 associations (eg, correlation and covariance)
  - 1.10.1.6 health impact (eg, risk differences and ratios)
  - 1.10.1.7 sensitivity, specificity, predictive values
- 1.10.2 fundamental concepts of study design
  - 1.10.2.1 types of experimental studies (eg, clinical trials, community intervention trials)
  - 1.10.2.2 types of observational studies (eg, cohort, case-control, cross-sectional, case series, community surveys)

- 1.10.2.3 sampling and sample size
- 1.10.2.4 subject selection and exposure allocation (eg, randomization, stratification, self-selection, systematic assignment)
- 1.10.2.5 outcome assessment
- 1.10.2.6 internal and external validity
- 1.10.3 fundamental concepts of hypothesis testing and statistical inference
  - 1.10.3.1 confidence intervals
  - 1.10.3.2 statistical significance and Type I error
  - 1.10.3.3 statistical power and Type II error

## **2. Hematopoietic and Lymphoreticular Systems**

### **2.1 Normal processes**

- 2.1.1 embryonic development, fetal maturation, and perinatal changes
- 2.1.2 organ structure and function
- 2.1.3 cell/tissue structure and function
  - 2.1.3.1 production and function of erythrocytes, hemoglobin, O<sub>2</sub> and CO<sub>2</sub> transport, transport proteins
  - 2.1.3.2 production and function of leukocytes and the lymphoreticular system
  - 2.1.3.3 production and function of platelets
  - 2.1.3.4 production and function of coagulation and fibrinolytic factors
- 2.1.4 repair, regeneration, and changes associated with stage of life

### **2.2 Abnormal processes**

- 2.2.1 infectious, inflammatory, and immunologic disorders
  - 2.2.1.1 infections of the blood, reticuloendothelial system, and lymphatics
  - 2.2.1.2 allergic and anaphylactic reactions and other immunopathologic mechanisms
  - 2.2.1.3 acquired disorders of immune deficiency
  - 2.2.1.4 autoimmunity and autoimmune diseases (eg, Coombs positive hemolytic anemia, cryoglobulinemias, ITP)
  - 2.2.1.5 anemia of chronic disease
  - 2.2.1.6 transfusion complications, transplant rejection
- 2.2.2 traumatic and mechanical injury (eg, mechanical injury to erythrocytes, splenic rupture)
- 2.2.3 neoplastic disorders
  - 2.2.3.1 lymphoma (eg, Hodgkin disease and non-Hodgkin lymphoma) and lymphocytic leukemia
  - 2.2.3.2 acute myelocytic leukemia, myelodysplastic states
  - 2.2.3.3 chronic myelocytic leukemia, myeloproliferative disorders
  - 2.2.3.4 multiple myeloma, dysproteinemias, amyloidosis
- 2.2.4 metabolic and regulatory disorders, including acquired and congenital
  - 2.2.4.1 anemias and cytopenias (eg, iron deficiency anemia, hemoglobinopathies, hereditary spherocytosis)
  - 2.2.4.2 cythemia
  - 2.2.4.3 hemorrhagic and hemostatic disorders (eg, coagulopathies, DIC)
  - 2.2.4.4 bleeding secondary to platelet disorders (eg, von Willebrand)
- 2.2.5 vascular and endothelial disorders (eg, effects and complications of splenectomy, hypersplenism, TTP, hemolytic-uremic syndrome)

- 2.2.6 systemic disorders affecting the hematopoietic and lymphoreticular system (eg, nutritional deficiencies, systemic lupus erythematosus)
- 2.2.7 idiopathic disorders

### **2.3 Principles of therapeutics**

- 2.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the hematopoietic system
  - 2.3.1.1 blood and blood products
  - 2.3.1.2 treatment of anemia, drugs stimulating erythrocyte production (eg, erythropoietin)
  - 2.3.1.3 drugs stimulating leukocyte production (eg, G-CSF, GM-CSF)
  - 2.3.1.4 anticoagulants, thrombolytic drugs
  - 2.3.1.5 antiplatelet drugs
  - 2.3.1.6 antimicrobials (eg, antimalarials, anti-HIV)
  - 2.3.1.7 antineoplastic and immunosuppressive drugs
  - 2.3.1.8 drugs used to treat acquired disorders of immune responsiveness
- 2.3.2 other therapeutic modalities (eg, splenectomy, chelating agents, radiation therapy for lymphomas, plasmapheresis)

### **2.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 2.4.1 emotional and behavioral factors (eg, diet, depression and immune responses, “blood doping” among athletes)
- 2.4.2 influence on person, family, and society (eg, childhood leukemia)
- 2.4.3 occupational and other environmental risk factors (eg, heavy metals, hydrocarbons, lead)
- 2.4.4 gender and ethnic factors (eg, herbal treatments with bone marrow depression)

## **3. Central and Peripheral Nervous Systems**

### **3.1 Normal processes**

- 3.1.1 embryonic development, fetal maturation, and perinatal changes, including neural tube derivatives, cerebral ventricles, neural crest derivatives
- 3.1.2 organ structure and function
  - 3.1.2.1 spinal cord
    - 3.1.2.1.1 gross anatomy and blood supply
    - 3.1.2.1.2 spinal reflexes
  - 3.1.2.2 brain stem
  - 3.1.2.3 brain
    - 3.1.2.3.1 gross anatomy and blood supply
    - 3.1.2.3.2 higher function: cognition, language, memory
    - 3.1.2.3.3 hypothalamic function
    - 3.1.2.3.4 limbic system and emotional behavior
    - 3.1.2.3.5 circadian rhythms and sleep
    - 3.1.2.3.6 control of eye movement
  - 3.1.2.4 sensory systems
    - 3.1.2.4.1 general sensory modalities, including proprioception and pain
    - 3.1.2.4.2 special sensory modalities, including vision, hearing, balance, taste, and olfaction

- 3.1.2.5 motor systems
  - 3.1.2.5.1 brain and spinal cord
  - 3.1.2.5.2 basal ganglia and cerebellum
- 3.1.2.6 autonomic nervous system
- 3.1.2.7 peripheral nerve
- 3.1.3 cell/tissue structure and function
  - 3.1.3.1 axonal transport
  - 3.1.3.2 excitable properties of neurons, axons and dendrites, including channels
  - 3.1.3.3 synthesis, storage, release, reuptake, and degradation of neurotransmitters and neuromodulators
  - 3.1.3.4 pre- and postsynaptic receptor interactions, trophic and growth factors
  - 3.1.3.5 brain metabolism
  - 3.1.3.6 glia, myelin
  - 3.1.3.7 brain homeostasis: blood-brain barrier; cerebrospinal fluid formation and flow; choroid plexus
- 3.1.4 repair, regeneration, and changes associated with stage of life

## 3.2 Abnormal processes

- 3.2.1 infectious, inflammatory, and immunologic disorders
  - 3.2.1.1 infectious disorders (eg, meningitis, abscess, encephalitis)
  - 3.2.1.2 demyelinating disorders, including multiple sclerosis, Guillain-Barré syndrome
  - 3.2.1.3 myasthenia gravis
  - 3.2.1.4 eye and ear (eg, conjunctivitis, otitis media)
- 3.2.2 traumatic and mechanical disorders (eg, subdural and epidural hematomas, cord compression, peripheral nerve injury)
- 3.2.3 neoplastic disorders
  - 3.2.3.1 primary (eg, meningioma, astrocytoma)
  - 3.2.3.2 metastatic
- 3.2.4 acquired metabolic and regulatory disorders (eg, delirium, ~~Reye syndrome~~)
- 3.2.5 vascular disorders (eg, cerebrovascular occlusion, venous sinus thrombosis, arterial aneurysms, hemorrhage)
- 3.2.6 systemic disorders affecting the nervous system (eg, lupus, diabetic neuropathy)
- 3.2.7 idiopathic disorders affecting the nervous system
- 3.2.8 congenital disorders, including metabolic (eg, neural tube defects, cerebral palsy, mental retardation, Down syndrome)
- 3.2.9 degenerative disorders (eg, peripheral neuropathy, Alzheimer dementia, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis)
- 3.2.10 paroxysmal disorders (eg, epilepsy, headache, sleep disorders [narcolepsy, restless legs syndrome/periodic limb movement, circadian rhythm disorders, parasomnias], pain syndromes)
- 3.2.11 disorders of special senses (eg, blindness, deafness)
- 3.2.12 psychopathologic disorders, processes and their evaluation
  - 3.2.12.1 early-onset disorders (eg, learning disorders)
  - 3.2.12.2 disorders related to substance use
  - 3.2.12.3 schizophrenia and other psychotic disorders
  - 3.2.12.4 mood disorders

- 3.2.12.5 anxiety disorders
- 3.2.12.6 somatoform disorders
- 3.2.12.7 personality disorders
- 3.2.12.8 physical and sexual abuse of children, adults, and elders
- 3.2.12.9 other disorders (eg, dissociative, impulse control)

### **3.3 Principles of therapeutics**

- 3.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the nervous system
  - 3.3.1.1 anesthetics
  - 3.3.1.2 hypnotics
  - 3.3.1.3 psychopharmacologic agents (eg, anxiolytics, antidepressants, antipsychotic agents, mood-stabilizing agents)
  - 3.3.1.4 anticonvulsants
  - 3.3.1.5 analgesics
  - 3.3.1.6 stimulants, amphetamines
  - 3.3.1.7 antiparkinsonian drugs
  - 3.3.1.8 skeletal muscle relaxants; botulinum toxin
  - 3.3.1.9 neuromuscular junction blocking agents (including postsynaptic)
  - 3.3.1.10 antiglaucoma drugs
  - 3.3.1.11 drugs used to decrease intracranial pressure (eg, mannitol, high-dose glucocorticoids)
  - 3.3.1.12 antimigraine agents
  - 3.3.1.13 drugs affecting autonomic nervous system (eg, anticholinesterases)
- 3.3.2 other therapeutic modalities (eg, radiation, CFS shunting, surgery)

### **3.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 3.4.1 emotional and behavioral factors (eg, drug abuse, dementia, sleep deprivation, accident prevention, pets)
- 3.4.2 influence on person, family, and society (eg, developmental disabilities, dementia, generation reversal, nutrition, seizures, sleep disorders)
- 3.4.3 occupational and other environmental risk factors (eg, boxing, carbon monoxide exposure)
- 3.4.4 gender and ethnic factors

## **4. Skin and Related Connective Tissue**

### **4.1 Normal processes**

- 4.1.1 embryonic development, fetal maturation, and perinatal changes
- 4.1.2 organ structure and function
- 4.1.3 cell/tissue structure and function, including barrier functions, thermal regulation, eccrine function
- 4.1.4 repair, regeneration, and changes associated with stage of life or ethnicity (eg, senile purpura, male pattern baldness, postmenopausal hair changes)
- 4.1.5 skin defense mechanisms and normal flora

### **4.2 Abnormal processes**

- 4.2.1 infectious, inflammatory, and immunologic disorders

- 4.2.1.1 bacterial infections (eg, acne, cellulitis, carbuncle, abscess, necrotizing fasciitis, gangrene)
- 4.2.1.2 viral infections (eg, herpes infections, chickenpox, rubella, measles, roseola, verrucae)
- 4.2.1.3 fungal infections, including mycoses, dermatophytosis (eg, tinea)
- 4.2.1.4 parasitic infections (eg, scabies, lice)
- 4.2.1.5 immune and autoimmune disorders (eg, discoid lupus erythematosus, scleroderma, dermatomyositis, alopecia, psoriasis, urticaria, allergic dermatosis)
- 4.2.2 traumatic and mechanical disorders
  - 4.2.2.1 thermal injury
  - 4.2.2.2 decubitus ulcers
  - 4.2.2.3 effects of ultraviolet light and radiation
- 4.2.3 neoplastic disorders
  - 4.2.3.1 keratinocytes (eg, seborrheic keratosis, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, ichthyosis)
  - 4.2.3.2 melanocytes (eg, nevi, melanoma)
  - 4.2.3.3 vascular neoplasms (eg, hemangiomas, Kaposi sarcoma)
  - 4.2.3.4 other (eg, T-cell lymphoma, skin appendage tumors)
- 4.2.4 metabolic, regulatory, and structural disorders, (eg, vitamin deficiencies, hypervitaminosis, hyperhidrosis)
- 4.2.5 vascular disorders (eg, vasculitis, Raynaud disease)
- 4.2.6 systemic disorders affecting the skin (eg, Ehlers-Danlos syndrome, Marfan syndrome)

### **4.3 Principles of therapeutics**

- 4.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the skin and connective tissue
  - 4.3.1.1 anti-inflammatory agents (eg, corticosteroids, antihistamines)
  - 4.3.1.2 emollients
  - 4.3.1.3 sunscreen
  - 4.3.1.4 retinoids
  - 4.3.1.5 antimicrobial agents
  - 4.3.1.6 cytotoxic and immunologic therapy (eg, methotrexate, PUVA, keratinolytics)
- 4.3.2 other therapeutic modalities (eg, laser, tattoo removal, cryotherapy)

### **4.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 4.4.1 emotional and behavioral factors (eg, sun exposure, acne)
- 4.4.2 influence on person, family, and society (eg, psoriasis)
- 4.4.3 occupational and other environmental risk factors
- 4.4.4 gender and ethnic factors (eg, keloid)

## **5. Musculoskeletal System**

### **5.1 Normal processes**

- 5.1.1 embryonic development, fetal maturation, and perinatal changes
- 5.1.2 organ structure and function
- 5.1.3 cell/tissue structure and function

- 5.1.3.1 biology of bones, joints, tendons, skeletal muscle
- 5.1.3.2 exercise and physical conditioning
- 5.1.4 repair, regeneration, and changes associated with stage of life

## **5.2 Abnormal processes**

- 5.2.1 infectious, inflammatory, and immunologic disorders
  - 5.2.1.1 infectious disorders (eg, septic arthritis, Lyme disease, osteomyelitis)
  - 5.2.1.2 inflammatory disorders (eg, fibrositis, synovitis, tenosynovitis) (includes costochondritis)
  - 5.2.1.3 immunologic disorders (eg, rheumatoid arthritis, ankylosing spondylitis, polymyositis, systemic lupus erythematosus, dermatomyositis, polymyalgia rheumatica)
- 5.2.2 traumatic and mechanical disorders
  - 5.2.2.1 fractures
  - 5.2.2.2 sprains, strains, dislocations
  - 5.2.2.3 repetitive motion injuries (eg, carpal tunnel syndrome)
- 5.2.3 neoplastic disorders (eg, osteosarcoma, metastatic disease)
- 5.2.4 metabolic, regulatory, and structural disorders
  - 5.2.4.1 disorders of musculoskeletal development (eg, dwarfism, osteogenesis imperfecta)
  - 5.2.4.2 osteomalacia, osteoporosis, osteodystrophy
  - 5.2.4.3 gout
  - 5.2.4.4 muscular dystrophy
- 5.2.5 vascular disorders (eg, polyarteritis nodosa, bone infarcts)
- 5.2.6 systemic disorders affecting the musculoskeletal system (eg, diabetes mellitus)
- 5.2.7 idiopathic disorders (eg, Dupuytren contracture, scoliosis, Paget disease)
- 5.2.8 degenerative disorders (eg, disc disease, osteoarthritis)

## **5.3 Principles of therapeutics**

- 5.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the musculoskeletal system
  - 5.3.1.1 nonsteroidal anti-inflammatory drugs and analgesics
  - 5.3.1.2 muscle relaxants
  - 5.3.1.3 antigout therapy (eg, allopurinol, colchicine, uricosuric drugs)
  - 5.3.1.4 immunosuppressive drugs (eg, glucocorticoids, gold, cytotoxic agents)
  - 5.3.1.5 drugs affecting bone mineralization (eg, bisphosphonates, calcitonin, estrogen analogs)
- 5.3.2 other therapeutic modalities (eg, radiation, surgery, casts, rehabilitation)

## **5.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 5.4.1 emotional and behavioral factors (eg, diet, exercise, seat belts, bicycle helmets)
- 5.4.2 influence on person, family, and society (eg, osteoporosis, fractures in elderly, alcohol abuse and fractures)
- 5.4.3 occupational and other environmental risk factors (eg, athletes, musicians)
- 5.4.4 gender and ethnic factors (eg, bone mass)

## 6. Respiratory System

### 6.1 Normal processes

- 6.1.1 embryonic development, fetal maturation, and perinatal changes
- 6.1.2 organ structure and function
  - 6.1.2.1 airways, including mechanics and regulation of breathing
  - 6.1.2.2 lung parenchyma, including ventilation, perfusion, gas exchange
  - 6.1.2.3 pleura
  - 6.1.2.4 nasopharynx, sinuses
- 6.1.3 cell/tissue structure and function, including surfactant formation, alveolar structure
- 6.1.4 repair, regeneration, and changes associated with stage of life
- 6.1.5 pulmonary defense mechanisms and normal flora

### 6.2 Abnormal processes

- 6.2.1 infectious, inflammatory, and immunologic disorders
  - 6.2.1.1 infectious diseases
    - 6.2.1.1.1 infectious diseases of the upper respiratory tract (eg, sinusitis, pharyngitis)
    - 6.2.1.1.2 acute infectious diseases of the lower respiratory tract and pleura and their complications (eg, pneumonia, bronchiectasis, abscess, empyema)
    - 6.2.1.1.3 chronic infectious diseases of the lower respiratory tract (eg, Mycobacterium, endemic fungal infections, Nocardia/ Actinomyces)
  - 6.2.1.2 immunologic disorders
    - 6.2.1.2.1 allergic and hypersensitivity disorders (eg, asthma)
    - 6.2.1.2.2 autoimmune disorders (eg, Wegener granulomatosis, Goodpasture syndrome)
  - 6.2.1.3 inflammatory disorders
    - 6.2.1.3.1 pneumoconioses
    - 6.2.1.3.2 acute and chronic alveolar injury (eg, acute respiratory distress syndrome, chlorine gas/smoke inhalation)
    - 6.2.1.3.3 obstructive pulmonary disease
    - 6.2.1.3.4 restrictive pulmonary disease (eg, sarcoidosis, idiopathic fibrosis)
- 6.2.2 traumatic and mechanical disorders (eg, foreign body aspiration, pneumothorax, atelectasis, sleep apnea)
- 6.2.3 neoplastic disorders
  - 6.2.3.1 upper airway (eg, polyps)
  - 6.2.3.2 lower airway and lung parenchyma (eg, bronchogenic carcinoma, carcinoid tumors, bronchial adenoma)
  - 6.2.3.3 pleura (eg, mesothelioma)
  - 6.2.3.4 metastatic tumors
- 6.2.4 metabolic, regulatory, and structural disorders (eg, hypoventilation, disorders of gas exchange, ventilation-perfusion imbalance, neonatal respiratory distress syndrome)
- 6.2.5 vascular and circulatory disorders
  - 6.2.5.1 thromboembolic disease

- 6.2.5.2 pulmonary hypertension
- 6.2.5.3 pulmonary edema
- 6.2.5.4 pleural effusion
- 6.2.6 systemic disorders affecting the respiratory system

### **6.3 Principles of therapeutics**

- 6.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the respiratory system
  - 6.3.1.1 decongestants, cough suppressants, expectorants, mucolytics
  - 6.3.1.2 bronchodilator drugs
  - 6.3.1.3 anti-inflammatory and cytotoxic drugs
  - 6.3.1.4 antimicrobial agents
  - 6.3.1.5 antineoplastic agents
- 6.3.2 other therapeutic modalities (eg, oxygen therapy, nasal CPAP, mechanical ventilation, physical therapy, surgical procedures, including transplantation)

### **6.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 6.4.1 emotional and behavioral factors (eg, smoking, substance abuse, pets and allergies)
- 6.4.2 influence on person, family, and society (eg, tuberculosis, asthma, chronic obstructive pulmonary disease, school issues, protective parents, family smoking)
- 6.4.3 occupational and other environmental risk factors
- 6.4.4 gender and ethnic factors (eg, sarcoidosis, lung cancer)

## **7. Cardiovascular System**

### **7.1 Normal processes**

- 7.1.1 embryonic development, fetal maturation, and perinatal changes
- 7.1.2 organ structure and function
  - 7.1.2.1 chambers, valves
  - 7.1.2.2 cardiac cycle, mechanics, heart sounds, cardiac conduction
  - 7.1.2.3 hemodynamics, including systemic, pulmonary, coronary, and blood volume
  - 7.1.2.4 circulation in specific vascular beds
- 7.1.3 cell/tissue structure and function
  - 7.1.3.1 heart muscle, metabolism, oxygen consumption, biochemistry, and secretory function (eg, atrial natriuretic peptide)
  - 7.1.3.2 endothelium and secretory function, vascular smooth muscle, microcirculation, and lymph flow
    - 7.1.3.2.1 mechanisms of atherosclerosis
  - 7.1.3.3 neural and hormonal regulation of the heart, blood vessels, and blood volume, including responses to change in posture, exercise, and tissue metabolism
- 7.1.4 repair, regeneration, and changes associated with stage of life

### **7.2 Abnormal processes**

- 7.2.1 infectious, inflammatory, and immunologic disorders
  - 7.2.1.1 infectious disorders (eg, endocarditis, myocarditis, pericarditis)

- 7.2.1.2 inflammatory and immunologic disorders (eg, acute rheumatic fever, systemic lupus erythematosus, vasculitis, temporal arteritis)
- 7.2.2 traumatic and mechanical disorders (eg, tamponade, valvular disease, obstructive cardiomyopathy)
- 7.2.3 neoplastic disorders
- 7.2.4 metabolic and regulatory disorders
  - 7.2.4.1 dysrhythmias
  - 7.2.4.2 systolic and diastolic dysfunction, low- and high-output heart failure, cor pulmonale (eg, dilated cardiomyopathies)
  - 7.2.4.3 systemic hypertension
  - 7.2.4.4 ischemic heart disease, myocardial infarction
  - 7.2.4.5 systemic hypotension and shock
- 7.2.5 vascular disorders (eg, aneurysms, occlusions, varicosities, atherosclerosis)
- 7.2.6 systemic diseases affecting the cardiovascular system (eg, amyloidosis, aortic dissection with Marfan syndrome, scleroderma)
- 7.2.7 congenital disorders of the heart and central vessels

### **7.3 Principles of therapeutics**

- 7.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the cardiovascular system
  - 7.3.1.1 coronary and peripheral vasodilators
  - 7.3.1.2 antiarrhythmic drugs
  - 7.3.1.3 antihypertensive drugs
  - 7.3.1.4 measures used to combat hypotension and shock
  - 7.3.1.5 drugs affecting cholesterol and lipid metabolism
  - 7.3.1.6 drugs affecting blood coagulation, thrombolytic agents
  - 7.3.1.7 inotropic agents and treatment of heart failure
  - 7.3.1.8 immunosuppressive and antimicrobial drugs
  - 7.3.1.9 drugs to treat peripheral arterial disease
- 7.3.2 other therapeutic modalities (eg, pacemakers, angioplasty, valves, grafts, other surgical procedures)

### **7.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 7.4.1 emotional and behavioral factors (eg, smoking, alcohol, ischemic heart disease, obesity, exercise, diet)
- 7.4.2 influence on person, family, and society (eg, altered lifestyle)
- 7.4.3 occupational and other environmental risk factors (eg, stress)
- 7.4.4 gender and ethnic factors (eg, hypertension)

## **8. Gastrointestinal System**

### **8.1 Normal processes**

- 8.1.1 embryonic development, fetal maturation, and perinatal changes
- 8.1.2 organ structure and function
  - 8.1.2.1 anatomy of alimentary canal, including mouth, pharynx, esophagus, stomach, small intestine, large intestine, anus
  - 8.1.2.2 liver and biliary system, including enterohepatic circulation
  - 8.1.2.3 salivary glands and exocrine pancreas
  - 8.1.2.4 motility, including vomiting and defecation

- 8.1.2.5 digestion and absorption
- 8.1.3 cell/tissue structure and function
  - 8.1.3.1 endocrine and neural regulatory functions, including GI hormones (eg, gastrin)
  - 8.1.3.2 salivary, gastrointestinal, pancreatic, hepatic secretory products, including enzymes, proteins, bile salts, and processes
  - 8.1.3.3 synthetic and metabolic functions of hepatocytes
- 8.1.4 repair, regeneration, and changes associated with stage of life
- 8.1.5 gastrointestinal defense mechanisms and normal flora

## **8.2 Abnormal processes**

- 8.2.1 infectious, inflammatory, and immunologic disorders
  - 8.2.1.1 infectious disorders (eg, peritonitis, hepatitis, gingivostomatitis, peptic ulcer, gastritis, esophagitis, traveler's diarrhea, food poisoning)
  - 8.2.1.2 inflammatory disorders (eg, cholecystitis, pancreatitis)
  - 8.2.1.3 immunologic disorders (eg, Crohn disease, ulcerative colitis)
- 8.2.2 traumatic and mechanical disorders
  - 8.2.2.1 malocclusion
  - 8.2.2.2 hiatal hernia
  - 8.2.2.3 obstruction (eg, volvulus, intussusception, esophageal atresia, annular pancreas, postsurgical obstruction)
  - 8.2.2.4 perforation of hollow viscus and blunt trauma
  - 8.2.2.5 inguinal, femoral, and abdominal wall hernias
  - 8.2.2.6 esophageal and intestinal diverticula (eg, Meckel diverticulum)
- 8.2.3 neoplastic disorders
  - 8.2.3.1 benign (eg, polyps)
  - 8.2.3.2 malignant
- 8.2.4 metabolic and regulatory disorders
  - 8.2.4.1 motility disorders (eg, esophageal reflux, neuropathy, achalasia, irritable bowel syndrome, paralytic ileus, Hirschsprung disease)
  - 8.2.4.2 malabsorption (eg, pancreatic insufficiency, sprue, lactose intolerance)
  - 8.2.4.3 hepatic failure, jaundice, encephalopathy, cirrhosis, ascites, biliary atresia)
  - 8.2.4.4 cholelithiasis, cholestasis
- 8.2.5 vascular disorders
  - 8.2.5.1 portal hypertension and esophageal varices
  - 8.2.5.2 hemorrhoids, anal fissure
  - 8.2.5.3 ischemia, angiodysplasia, thromboses, vasculitis
- 8.2.6 systemic disorders affecting the gastrointestinal system

## **8.3 Principles of therapeutics**

- 8.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the gastrointestinal system
  - 8.3.1.1 treatment and prophylaxis of peptic ulcer disease and gastroesophageal reflux (eg, antacids, antisecretory drugs, mucosal protective agents, antibiotics)
  - 8.3.1.2 drugs to alter gastrointestinal motility (eg, cathartics, antidiarrheal drugs, antiemetic drugs, prokinetic drugs)

- 8.3.1.3 fluid replacement (eg, oral rehydration)
- 8.3.1.4 pancreatic replacement therapy and treatment of pancreatitis
- 8.3.1.5 drugs for treatment of hepatic failure (eg, lactulose) and biliary disease (eg, drugs to dissolve gallstones)
- 8.3.1.6 anti-inflammatory, immunosuppressive, antineoplastic, and antimicrobial drugs
- 8.3.2 other therapeutic modalities (eg, surgical procedures, stents, feeding tubes)

#### **8.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 8.4.1 emotional and behavioral factors (eg, peptic ulcer, encopresis, Monday morning stomach)
- 8.4.2 influence on person, family, and society (eg, inflammatory bowel disease, irritable bowel disease, pancreatitis and alcohol, chronic laxative abuse)
- 8.4.3 occupational and other environmental risk factors
- 8.4.4 gender and ethnic factors (eg, diets)

### **9. Renal/urinary System**

#### **9.1 Normal processes**

- 9.1.1 embryonic development, fetal maturation, and perinatal changes
- 9.1.2 organ structure and function
  - 9.1.2.1 kidneys, ureters, bladder, urethra
  - 9.1.2.2 glomerular filtration and hemodynamics
  - 9.1.2.3 tubular reabsorption and secretion, including transport processes and proteins
  - 9.1.2.4 urinary concentration and dilution
  - 9.1.2.5 renal mechanisms in acid-base balance
  - 9.1.2.6 renal mechanisms in body fluid homeostasis
  - 9.1.2.7 micturition
- 9.1.3 cell/tissue structure and function
  - 9.1.3.1 renal metabolism and oxygen consumption
  - 9.1.3.2 hormones produced by or acting on the kidney
- 9.1.4 repair, regeneration, and changes associated with stage of life

#### **9.2 Abnormal processes**

- 9.2.1 infectious, inflammatory, and immunologic disorders
  - 9.2.1.1 infectious disorders
    - 9.2.1.1.1 upper urinary tract (eg, pyelonephritis, papillary necrosis)
    - 9.2.1.1.2 lower urinary tract (eg, cystitis, urethritis)
  - 9.2.1.2 inflammatory and immunologic disorders
    - 9.2.1.2.1 glomerular disorders (eg, glomerulonephritis, nephrotic syndrome, IgA nephropathy)
    - 9.2.1.2.2 tubular interstitial disease (eg, interstitial nephritis)
- 9.2.2 traumatic and mechanical disorders (eg, obstructive uropathy)
- 9.2.3 neoplastic disorders
  - 9.2.3.1 primary
    - 9.2.3.1.1 renal
    - 9.2.3.1.2 urinary bladder and collecting system

- 9.2.3.2 metastases
- 9.2.4 metabolic and regulatory disorders
  - 9.2.4.1 renal failure, acute and chronic (eg, acute tubular necrosis)
  - 9.2.4.2 tubular and collecting duct disorders (eg, Fanconi syndrome, renal tubular acidosis, nephrogenic diabetes insipidus, polycystic kidney disease)
  - 9.2.4.3 renal calculi
- 9.2.5 vascular disorders (eg, renal artery stenosis)
- 9.2.6 systemic diseases affecting the renal system (eg, diabetes mellitus, hepatitis, amyloid, systemic lupus erythematosus, Wegener granulomatosis)

### **9.3 Principles of therapeutics**

- 9.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the renal and urinary system
  - 9.3.1.1 diuretics, antidiuretic drugs
  - 9.3.1.2 drugs and fluids used to treat volume, electrolyte, and acid-base disorders
  - 9.3.1.3 drugs used to enhance renal perfusion (eg, dopamine)
  - 9.3.1.4 anti-inflammatory, antimicrobial, immunosuppressive, and antineoplastic drugs
  - 9.3.1.5 drugs used to treat lower urinary tract system (eg, incontinence, bladder function, benign prostatic hyperplasia)
- 9.3.2 other therapeutic modalities (eg, dialysis, renal transplantation)

### **9.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 9.4.1 emotional and behavioral factors (eg, drug-induced interstitial nephritis, diet)
- 9.4.2 influence on person, family, and society (eg, hemodialysis, living related kidney donation, transplants)
- 9.4.3 occupational and other environmental risk factors (eg, heavy metals)
- 9.4.4 gender and ethnic factors (eg, disease progression, urinary tract infections)

## **10. Reproductive System**

### **10.1 Normal processes**

- 10.1.1 embryonic development, fetal maturation, and perinatal changes
- 10.1.2 organ structure and function
  - 10.1.2.1 female structure, including breast
  - 10.1.2.2 female function (eg, menstrual cycle, puberty, menopause)
  - 10.1.2.3 male structure
  - 10.1.2.4 male function (eg, spermatogenesis, puberty)
  - 10.1.2.5 intercourse, orgasm
  - 10.1.2.6 pregnancy, ovulation, fertilization, implantation, including labor and delivery, the puerperium, lactation, gestational uterus, placenta
- 10.1.3 cell/tissue structure and function, including hypothalamic-pituitary-gonadal axis, sex steroids, gestational hormones
- 10.1.4 reproductive system defense mechanisms and normal flora

### **10.2 Abnormal processes**

- 10.2.1 infectious, inflammatory, and immunologic disorders

- 10.2.1.1 infectious disorders (eg, toxic shock syndrome, breast abscess, orchitis)
  - 10.2.1.1.1 sexually transmitted diseases
- 10.2.1.2 immunologic and inflammatory disorders (eg, autoimmune hypogonadism, cystic mastitis)
- 10.2.2 traumatic and mechanical disorders
  - 10.2.2.1 female incontinence, prolapse, cystocele
  - 10.2.2.2 torsion of testis, varicocele, circumcision, phimosis
- 10.2.3 neoplastic disorders
  - 10.2.3.1 female reproductive (eg, cervix, ovary)
  - 10.2.3.2 male reproductive (eg, prostate)
  - 10.2.3.3 breast, including fibrocystic changes
  - 10.2.3.4 trophoblastic disease
- 10.2.4 metabolic and regulatory processes
  - 10.2.4.1 female (eg, anovulation, infertility, polycystic ovaries, endometriosis, orgasmic dysfunction, delayed and premature puberty)
    - 10.2.4.1.1 menopausal syndrome
  - 10.2.4.2 male (eg, infertility, impotence, gynecomastia, delayed and premature puberty)
    - 10.2.4.2.1 benign prostatic hyperplasia
- 10.2.5 systemic disorders affecting reproductive function (eg, obesity, myotonic dystrophy, cirrhosis, renal failure)
- 10.2.6 Reserved
- 10.2.7 disorders relating to pregnancy, the puerperium, and the postpartum period
  - 10.2.7.1 obstetric problems (eg, ectopic pregnancy, third-trimester bleeding)
  - 10.2.7.2 complications affecting other organ systems (eg, eclampsia, gestational diabetes, thyroid disorders)
  - 10.2.7.3 disorders associated with the puerperium (eg, postpartum hemorrhage, sepsis, depression)
  - 10.2.7.4 antepartum, intrapartum, postpartum disorders of the fetus (eg, prematurity, postmaturity, cord compression, macrosomia)

### **10.3 Principles of therapeutics**

- 10.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the reproductive system and management of normal reproductive function
  - 10.3.1.1 female reproductive tract
    - 10.3.1.1.1 fertility drugs
    - 10.3.1.1.2 oral contraception, other methods of contraception (eg, condoms)
    - 10.3.1.1.3 estrogen, progestogen replacement, treatment of menopause
    - 10.3.1.1.4 stimulants and inhibitors of labor
    - 10.3.1.1.5 estrogen and progesterone antagonists
    - 10.3.1.1.6 stimulators and inhibitors of lactation
  - 10.3.1.2 male reproductive tract
    - 10.3.1.2.1 fertility drugs
    - 10.3.1.2.2 androgen replacement and antagonists
  - 10.3.1.3 gonadotropin-releasing hormone and gonadotropin replacement

- 10.3.1.4 abortifacients
- 10.3.1.5 antimicrobials
- 10.3.1.6 antineoplastics
- 10.3.1.7 restoration of potency
- 10.3.2 other therapeutic modalities affecting the reproductive system (eg, tampons)

#### **10.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 10.4.1 emotional and behavioral factors (eg, sexually transmitted diseases)
- 10.4.2 influence on person, family, and society (eg, infertility)
- 10.4.3 occupational and other environmental risk factors (eg, radiation)
- 10.4.4 family planning and pregnancy (eg, unwanted)
- 10.4.5 gender identity, sexual orientation, sexuality, libido
- 10.4.6 effects of traumatic stress syndrome, violence, rape, child abuse

### **11. Endocrine System**

#### **11.1 Normal processes**

- 11.1.1 embryonic development, fetal maturation, and perinatal changes
- 11.1.2 organ structure and function
  - 11.1.2.1 hypothalamus, posterior and anterior pituitary gland
  - 11.1.2.2 thyroid gland
  - 11.1.2.3 parathyroid glands
  - 11.1.2.4 adrenal cortex, adrenal medulla
  - 11.1.2.5 pancreatic islets
  - 11.1.2.6 ovary and testis
  - 11.1.2.7 adipose tissue
- 11.1.3 cell/tissue structure and function, including hormone synthesis, secretion, action, and metabolism
  - 11.1.3.1 peptide hormones
  - 11.1.3.2 steroid hormones, including vitamin D
  - 11.1.3.3 thyroid hormones
  - 11.1.3.4 catecholamine hormones
  - 11.1.3.5 renin-angiotensin system
- 11.1.4 repair, regeneration, and changes associated with stage of life

#### **11.2 Abnormal processes**

- 11.2.1 infectious, inflammatory, and immunologic disorders
  - 11.2.1.1 infectious disorders (eg, subacute thyroiditis, mumps)
  - 11.2.1.2 immunologic disorders (eg, Graves disease, Hashimoto disease)
  - 11.2.1.3 inflammatory disorders (eg, sarcoidosis)
- 11.2.2 traumatic and mechanical disorders
- 11.2.3 neoplastic disorders
  - 11.2.3.1 pituitary (including craniopharyngioma)
  - 11.2.3.2 thyroid
  - 11.2.3.3 parathyroid
  - 11.2.3.4 adrenal cortex
  - 11.2.3.5 pancreatic islets
  - 11.2.3.6 neural crest, pheochromocytoma
- 11.2.4 metabolic and regulatory processes

- 11.2.4.1 diabetes mellitus (types I and II), ketoacidosis, hyperosmolar coma
- 11.2.4.2 pituitary, hypothalamus (eg, central diabetes insipidus, syndrome of inappropriate secretion of ADH, hypopituitarism, acromegaly)
- 11.2.4.3 thyroid (eg, hypothyroidism, thyrotoxicosis), euthyroid sick syndrome
- 11.2.4.4 parathyroid (eg, hyperparathyroidism, hypoparathyroidism), hypocalcemia, hypercalcemia, metabolic bone disorders
- 11.2.4.5 pancreatic islet disorders (eg, hyperinsulinism)
- 11.2.4.6 adrenal disorders (eg, Cushing syndrome, adrenocortical insufficiency, hyperaldosteronism)
- 11.2.5 vascular disorders (eg, pituitary apoplexy)
- 11.2.6 systemic disorders affecting the endocrine system
- 11.2.7 idiopathic disorders (eg, hirsutism)

### **11.3 Principles of therapeutics**

- 11.3.1 mechanisms of action, use, and adverse effects of drugs for treatment of disorders of the endocrine system
  - 11.3.1.1 hormones and hormone analogs
  - 11.3.1.2 stimulators of hormone production (eg, sulfonylureas)
  - 11.3.1.3 inhibitors of hormone production (eg, thiouracils)
  - 11.3.1.4 hormone antagonists
  - 11.3.1.5 potentiators of hormone action (eg, thiazolidinediones)
  - 11.3.1.6 antiobesity agents
- 11.3.2 other therapeutic modalities (eg, surgery, radiation)

### **11.4 Gender, ethnic, and behavioral considerations affecting disease treatment and prevention, including psychosocial, cultural, occupational, and environmental**

- 11.4.1 emotional and behavioral factors (eg, compliance in diabetes mellitus, factitious use of insulin, psychogenic polydipsia)
- 11.4.2 influence on person, family, and society
- 11.4.3 occupational and other environmental risk factors (eg, radiation exposure, iodine deficiency)
- 11.4.4 gender and ethnic factors